ssDNA Aptamers Targeting Alpha-Synuclein Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapeutic approaches for neurodegenerative diseases like Parkinson's, which rely on antibodies, face challenges such as difficulty accessing intracellular compartments, inability to cross the blood-brain barrier, and high immunogenicity, limiting their effectiveness in targeting alpha-synuclein aggregates.
Innovation Solution
Development of novel single-stranded DNA (ssDNA) aptamers specifically targeting fibrillar forms of truncated alpha-synuclein, which offer advantages like non-immunogenicity, high thermal stability, and cost-effectiveness, and can inhibit alpha-synuclein aggregation and phosphorylation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies are used for immunotherapy targeting alpha-synuclein aggregates, then specific binding to alpha-synuclein can be achieved, but the ability to access intracellular compartments and cross blood-brain barrier is limited
Solution Approach 1:
The patent uses aptamers as a simplified copy or alternative to antibodies. Instead of using large antibody molecules that cannot access intracellular compartments, the invention employs smaller aptamer molecules that can penetrate into cells and bind to intracellular alpha-synuclein aggregates with high specificity, thus resolving the contradiction between binding reliability and ease of operation.
2Reliability
If antibodies are used for immunotherapy, then alpha-synuclein aggregation can be targeted, but high immunogenicity limits effectiveness
Solution Approach 1:
The patent employs aptamers as short-lived, non-immunogenic alternatives to antibodies. Aptamers are synthetic oligonucleotides that do not trigger immune responses like antibodies do, thereby eliminating the harmful immunogenicity effect while maintaining therapeutic effectiveness against alpha-synuclein aggregation.
3Reliability
If conventional antibody production methods are used, then specific alpha-synuclein binding can be achieved, but high cost and complex manufacturing process result
Solution Approach 1:
The patent replaces the complex biological system of antibody production (involving immunization, cell culture, purification) with a simpler in vitro selection process for aptamers. This substitution of the production mechanism dramatically reduces manufacturing cost and complexity while maintaining high binding specificity to alpha-synuclein.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ssDNA aptamers effectively inhibit alpha-synuclein aggregation and phosphorylation, demonstrating potential as a promising therapeutic strategy for Parkinson's disease and other synucleinopathies by specifically binding to truncated alpha-synuclein forms without cross-reactivity with other amyloid proteins.
Implementation Method 1
Aptamers can bind to a wide range of targets ranging from simple inorganic molecules to large protein complexes and cells with high affinity and specificity
Data Source
AI summary
The present disclosure, in part, relates to novel, aptamers targeting α-synuclein. The present disclosure includes methods for making and methods of using aptamers targeting α-synuclein.